BioNTech SE

Moderna and Merck hailed preliminary results from a combination therapy as a breakthrough, but there are important nuances to consider.

A vaccine candidate from Vaxcyte appears to offer better protection against bacterial infections than the Prevnar franchise from Pfizer.

"Together we have made significant progress in advancing mRNA-4157 as an investigational personalized cancer treatment used in combination with (Merck & Co.'s) Keytruda," Moderna said Wednesday.

The new CEO is a perfect fit for the company's growth plans. Sales will decline sharply anyway.

"We believe that Pfizer and BioNTech unlawfully copied Moderna's inventions, and they have continued to use them without permission," Moderna said.

Pfizer held to its forecast of $54 billion in Covid related sales this year following stronger-than-expected second quarter earnings and record overall revenues.

“As the Covid pandemic continues to evolve and be highly unpredictable, we must remain vigilant in protecting those who are at greatest risk of getting very sick from Covid," said CEO Albert Bourla.

Jim Cramer cautions that knowing when the bottom has arrived and knowing when to buy back into the market is never easy. Don't risk missing out.

Fighting hidden coronavirus variants is like a whack-a-mole game and this company wants to try a new approach.

Moderna said it now sees sales of Spikevax rising to $19 billion this year, with additional signed options of approximately $3 billion.

Pfizer said combined sales of its Covid vaccine and treatment drugs would rise to $54 billion this year, around half of its total projected revenues.

The U.S. Food & Drug Administration has given its full and final approval for the use of Moderna's 'Spikevax' Covid vaccine, the drugmaker said Monday.

Pfizer is ready to provide 50 million to 100 million vaccine doses for people who are found positive with the omicron variant of the coronavirus if it is needed.

The collaboration will be based on mRNA technology and builds on Pfizer and BioNTech's successful effort to produce a Covid vaccine.

The efficacy of boosters against Covid-19 is likely to decline and people may need another shot in the fall of 2022, Moderna CEO Stephane Bancel says.

The FDA earlier this week issued emergency-use authorization for the Pfizer booster for kids ages 12 through 15.

Stocks set to rise despite record new Covid cases, AT&T and Verizon acquiesce to delaying 5G rollout, Walmart shuts stores for Covid cleaning and Theranos founder found guilty.

Stocks end higher on the first trading day of 2022 amid travel chaos brought on by the spread of the omicron variant.

The FDA also reduced the waiting period for the booster to five months after the second shot for people 12 and up.

Reverse carry trade? Well, that's at least how it started. Did you not think that bills must come due? Did you not think the bell would toll ultimately for thee?

Small-caps and mega-caps moving in tandem, Utes are on the rise, what could be better? Well, the math gets harder soon. Also, when to buy Nvidia, sell Microsoft and much more.

Markets appeared to be less than fully prepared that 'various [Fed] participants' had at least spoken about their willingness to maybe tighten monetary policy if need be.

Here's why market participants may get a chance to catch their collective breath this week.

Though both debt and equity markets strengthened on Tuesday, there was a clear lack of conviction ahead of the FOMC's square dance and hoedown.

Let's check the charts and indicators on BNTX.

Earnings season is winding down. Better than expected, as it always seems to be, but still not good.

New Covid infections appear to be surging in China due to the rise of the XBB sub-lineage of the Omicron variant.

The Fed still has a somewhat Pollyannaish view of where unemployment and inflation will go as the economy slows.

The stock is already down about 15% in 2023 as the pharmaceutical giant gets set to report earnings.

Wednesday morning will bring traders, investors, Romans, and countrymen more macroeconomic results than they could ever wanted to peruse at one time.

We expect Chinese travelers to return in large numbers, as Asian nations slap new restrictions on arrivals from the last major nation to learn to "live with Covid."

The notion that China will ease its zero-Covid policy spurs stocks higher even though there's no indication from the government of a pending change.

Of primary importance, from a macroeconomic perspective, the focus of the week will be the October CPI to be released on Thursday.

The latest China Covid shutdown will impact Toyota, Intel, and Foxconn Technology, which by extension possibly implies Apple.

It's difficult to see how this bill is a broad win on inflation.

There was a time when Covid vaccine news was headline material. Not now, though, and this news could matter.

China's ongoing fight against COVID threatens to make the going tough for companies that do business there.

The US may very well escape recession this year, putting it off until early next year. Other global economies may not be so lucky.

Mark Zuckerberg's AI team unveiled big plans for AI in an email chain

These 10 compact and midsized sport utility vehicles earned CR’s highest marks, and they sell for wallet-friendly prices.

Here’s what could be next in the AI boom.